Megan McCausland’s Post

APIS has been featured in the Bruntwood SciTech and Drug Discovery World whitepaper: 'Fuelling the future: Precision medicine innovation and the role of ecosystems' Check it out below!

Precision medicine innovation and the role of ecosystems This whitepaper, Fuelling the future: Precision medicine innovation and the role of ecosystems, examines how the future of drug discovery and precision medicine can be enhanced by life science ecosystems such as those created by the UK's leading property developer to the science and technology sectors, Bruntwood SciTech. In the whitepaper, you will discover: - The evolution of precision diagnostics for oncology in the North West of England - How life science ecosystems enable key breakthroughs in precision medicine - A view into the future of precision medicine developments. Download Whitepaper https://lnkd.in/eKYQ5d-M Brought to you by Bruntwood SciTech #PrecisionMedicine #DrugDiscovery #Diagnostics

Excited to attend this webinar to learn more about ISH technology, and how it can be applied to scientific research!

This Friday, November 3, from 12:40 - 1:40 PM, stop by the exhibit hall at the North American Cystic Fibrosis Conference to hear our Director of Research, Daniella Ishimaru, PhD, present her poster titled “First Generation Aerosolized Lipid Nanoparticle/mRNA Therapy Rescues CFTR Function in CF hBEs.” We look forward to sharing our research with you. Be sure to stop by Booth 804 before or after Dr. Ishimaru’s presentation to hear more about our CF Pipeline. Patients first—always. #cysticfibrosis #GeneticMedicine #NACFC

What makes a robust iPSC-derived atrial model? If you're looking to develop high-quality, chamber-specific cardiac models for research and toxicity screening, then we can help. Listen to this excerpt of our Senior Scientific Support Manager (and cardiomyocytes expert) Steven Broadbent as he distils over a decade of Axol Bioscience expertise into four steps that can produce a robust iPSC-derived atrial model. This is taken from Steven's masterclass "Building chamber-specific cardiac models with iPSCs" which covers: • Our learnings from over a decade in the cardiac iPSC space • The functional data supporting our atrial and ventricular cardiomyocytes (for use in chamber-specific models) • A look to the future of cardiotoxicity models Click here to access the full webinar recording: https://hubs.la/Q02xc6sG0 If you're working with iPSC-derived cardiomyocytes and would like to discuss how Axol Bioscience could help you to unlock the benefits of iPSC technology, get in touch at [email protected] #iPSCs #cardiotoxicity #CiPA #DrugDiscovery #AtrialFibrillation

Want to know how mass photometry can be used for forced antibody degradation assessment, a crucial aspect of research and development for recombinant mAb therapeutics? Register for the upcoming webinar by Refeyn on 6 Feb, 11pm* to get your answers! Click here: https://lnkd.in/dGEaX3tt *Those who registered will have access to the recorded webinar. Among the key learnings are: - How mass photometry enables rapid assessment of sample quality - How mass photometry complements other analytical methods for antibody sample characterization, such as SEC - What the sample requirements are for detection of antibody aggregates and fragments. Sciencewerke Pte Ltd Refeyn #massphotometry #rapidassessment #antibodysamplecharacterization #antibodyaggregates

Follow us and our Cluster member Miltenyi Biotec on the exciting journey from target validation via proof of principle in small scale to clinical scale: In three hybrid sessions and a hands-on demo day on the CliniMACS Prodigy we will focus on different stages of the development of cell- and genetherapies in our seminar series “From target validation to clinical application”. As an expert in the field,Miltenyi Biotec will help you set up your own experiments with exclusive tips and tricks based on more than 10 years of experience. In our first seminar we will talk about the potential of Spatial Biology for target identification and validation as well as possibilities for patient stratification using the MACSima Platform. Our second and third seminar will focus on how to translate a cellular therapy approach from the early benchtop experiments to a clinical scale production. 

What makes a robust iPSC-derived atrial model? If you're looking to develop high-quality, chamber-specific cardiac models for research and toxicity screening, then we can help. Listen to this excerpt of our Senior Scientific Support Manager (and cardiomyocytes expert) Steven Broadbent as he distils over a decade of Axol Bioscience expertise into four steps that can produce a robust iPSC-derived atrial model. This is taken from Steven's masterclass "Building chamber-specific cardiac models with iPSCs" which covers: • Our learnings from over a decade in the cardiac iPSC space • The functional data supporting our atrial and ventricular cardiomyocytes (for use in chamber-specific models) • A look to the future of cardiotoxicity models Click here to access the full webinar recording: https://hubs.la/Q02xc6Q00 If you're working with iPSC-derived cardiomyocytes and would like to discuss how Axol Bioscience could help you to unlock the benefits of iPSC technology, get in touch at [email protected] #iPSCs #cardiotoxicity #CiPA #DrugDiscovery #AtrialFibrillation

Imagine #flowcytometry, but on a tissue block. Check out this publication highlighting our novel, AI-enabled analytics for multiplex immunofluorescence (MxIF). Let me know if you have trouble accessing it using the link.

She is the reason. The truth is: no massive business challenge, no own ambitions, nothing could ignite us to use all of our talents and keep investing 200% of our engagement for 24 months, constantly. And she did. It all started on 14th of February, 2022 with Lena’s devastating diagnosis. For 2 years, we have fundraised and invested 430k USD to run a comprehensive set of 8 research projects aiming at drug discovery for PACS2 syndrome. It was THE ride. But the good one. We don’t do it only for Lena anymore. And something new is coming soon. 🚀 — You can join us in making it a good story: https://lnkd.in/dMAguf38 — Closing balance for 2023 / opening 2024: ✅ Research reagents ready (fibroblasts, iPSC, C. elegans and mouse models); ✅ 3 paths of translational research open and several other projects which can give new clues for PACS2 syndrome biology; ✅ shortlisted 70+ compounds which heal diseased cell to different extent 🔥 ✅ We became a member of several international assotiations for rare diseases: of European EURORDIS and ERN EpiCARE, and of Community Advisory Committee of Simons Searchlight; 🚀 We consult more and more European families which aim to cure other ultra rare diseases; 🚀 We are invited by our Partners at Oxford University to share our experience at UpNAT Inaugural Symposium [UpNAT is UK Platform of Nucleic Acid Therapy] 🚀 We are invited as speakers to 2 important Polish rare disease day’s events – at Warsaw Medical University and Institute of Biochemistry and Biophysics Polish Academy of Science 🚀 We intend to extend our activity 🤭 Stay with us! #research #drugdiscovery #pacs2 #dee66 #raredisease #rarediseasemonth